Teva wins FDA nod for new Austedo formulation
https://seekingalpha.com/news/4111457-teva-wins-fda-nod-new-austedo-version?source=feed_tag_israel
May 30, 2024 - Teva Pharmaceutical (TEVA) has gained FDA approval to market Austedo XR in four new dosing strengths in the U.S. Read more here.
0
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
https://www.zacks.com/stock/news/2277367/gsk-studies-on-depemokimab-for-severe-asthma-meet-primary-goals?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2277367
May 22, 2024 - GSK's depemokimab has the potential to become the first ultra-long-acting biologic for severe asthma with a six-month dosing schedule
0
Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript)
https://seekingalpha.com/article/4693194-teva-pharmaceutical-industries-limited-teva-bofa-securities-2024-health-care-conference?source=feed_tag_israel
May 14, 2024 - Teva Pharmaceutical Industries Limited (NYSE:NYSE:TEVA) BofA Securities 2024 Health Care Conference May 14, 2024 11:40 AM ETCompany ParticipantsJason...
0
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
https://www.zacks.com/stock/news/2272766/should-value-investors-buy-teva-pharmaceutical-industries-teva-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2272766
May 13, 2024 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
0
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
https://www.zacks.com/stock/news/2271674/teva-q1-earnings-miss-schizophrenia-study-meets-goal-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2271674
May 09, 2024 - TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.
0
Teva Pharmaceutical: 6 Takeaways From Q1 2024 Earnings Results
https://seekingalpha.com/article/4691222-teva-pharmaceutical-q1-2024-earnings-results-takeaways?source=feed_tag_israel
May 09, 2024 - Teva Pharmaceutical stock has been rising since Oct. 2023, reporting strong Q1 results and positive outlook for 2024. Check out my takeaways from TEVA earnings.
0
Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
https://seekingalpha.com/article/4691152-teva-sustained-revenue-growth-amid-financial-strain-rating-downgrade?source=feed_tag_israel
May 08, 2024 - Teva's blockbuster drugs continue to show robust growth and contribute to the company's revenue. See why TEVA stock is a Hold.
0
Teva Pharmaceutical Q1 2024 Earnings Preview
https://seekingalpha.com/news/4101255-teva-pharmaceutical-q1-2024-earnings-preview?source=feed_tag_israel
May 07, 2024 - Teva Pharmaceutical is set to announce Q1 earnings results on May 8th.
0
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
https://www.zacks.com/stock/news/2268837/watch-these-5-drug-stocks-for-q1-earnings-beat-or-miss?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2268837
May 06, 2024 - Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
0
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
https://www.cnbc.com/2024/04/30/ftc-challenges-patents-held-by-drugmakers-including-for-ozempic.html
Apr 30, 2024 - The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
0